Publicaciones en las que colabora con Ana Rouzaut Subirá (11)

2022

  1. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

    Cancer research, Vol. 82, Núm. 23, pp. 4373-4385

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

2016

  1. A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer

    Molecular Oncology, Vol. 10, Núm. 9, pp. 1437-1449

2015

  1. Functional expression of CD137 (4-1BB) on T helper follicular cells

    OncoImmunology, Vol. 4, Núm. 12

2014

  1. TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients

    British Journal of Cancer, Vol. 110, Núm. 6, pp. 1545-1551

2013

  1. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC

    International Journal of Cancer, Vol. 132, Núm. 9, pp. 1986-1995

2012

  1. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

    Journal of Immunology, Vol. 189, Núm. 9, pp. 4674-4683

2010

  1. TGFBI expression is associated with a better response to chemotherapy in NSCLC

    Molecular Cancer, Vol. 9

2008

  1. Analysis of TGFBI overexpression and silencing in the proliferation, migration and chemoresistance of NSCLC cells

    EJC SUPPLEMENTS

2007

  1. Lymphangiogenesis and lung cancer

    Journal of Thoracic Oncology, Vol. 2, Núm. 5, pp. 384-386

2005

  1. Targeting hypoxia and angiogenesis through HIF-1α inhibition

    Cancer Biology and Therapy, Vol. 4, Núm. 10, pp. 1055-1062